Sinopharm Group Co. Ltd. financial statements, including revenue, expenses, profit, and loss

The total revenue of SHTDY for the last semiannual is 40.84 B USD, and it's 5.93% lower compared to the previous semiannual. The net income of H2 23 is 683.82 M USD.